Takeda (TAK) Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy Oct 20, 2022 07:06AM
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy Oct 20, 2022 07:00AM
Takeda Pharmaceutical (TAK) and Arrowhead (ARWR) Announce Publication of Results from Phase 2 Study of Fazirsiran Jun 27, 2022 06:02AM
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Jun 27, 2022 06:00AM
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors Jan 10, 2022 07:00AM


Oct 27, 2021 09:15AM Takeda (TAK) to Acquire GammaDelta Therapeutics
Oct 27, 2021 09:15AM Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
Sep 16, 2020 03:00AM Takeda to Divest TachoSil® to Corza Health for €350 Million
May 8, 2019 06:30PM Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
Feb 21, 2019 07:35AM Nomura Starts Takeda Pharmaceutica (4502:JP) (TAK) at Buy